Skip to main content
Erschienen in: Cancer Causes & Control 8/2014

01.08.2014 | Original paper

Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage

verfasst von: Sheetal Hardikar, Xiaoling Song, Mario Kratz, Garnet L. Anderson, Patricia L. Blount, Brian J. Reid, Thomas L. Vaughan, Emily White

Erschienen in: Cancer Causes & Control | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Systemic measures of chronic inflammation, often based on a single blood draw, are frequently used to study the associations between inflammation and chronic diseases such as cancer. However, more information is needed on the measurement error in these markers due to laboratory error, within-person variation over time, and long-term storage.

Methods

We investigated the intraindividual variability of inflammation markers C-reactive protein (CRP), interleukin-6 (IL-6), and soluble tumor necrosis factor receptors I and II (sTNFRI and II) in a subsample of the Seattle Barrett’s esophagus study cohort. Two fasting blood samples were collected between 1995 and 2009 from 360 participants on average 1.8 years apart. CRP, IL-6, and sTNF receptor levels were measured by immunonephelometry, ELISA, and multiplex assays, respectively. Intra- and inter-batch coefficients of variation (CV) were estimated using blinded pooled samples within each batch. Intraclass correlations (ICCs) were computed using random effects ANOVA.

Results

Intra- and inter-batch CVs for the pooled plasma aliquots were low (2.4–8.9 %), suggesting little laboratory variability. Reliability over time was excellent for sTNF receptors (ICCsTNF-RI = 0.89, ICCsTNF-RII = 0.85) and fair-to-good for CRP and IL-6 (ICCCRP = 0.55, ICCIL-6 = 0.57). For samples stored for over 13 years, the ICCs for CRP and IL-6 were decreased but those for sTNF receptors were unaffected.

Conclusion

sTNF receptor levels are more stable within person over time than CRP or IL-6. Long-term storage of samples appears to increase the variability of CRP and IL-6 measures, while the reliability of soluble TNF receptor measures was not affected by storage time.
Literatur
1.
Zurück zum Zitat Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef
2.
Zurück zum Zitat Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14:2413–2418PubMedCrossRef Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14:2413–2418PubMedCrossRef
3.
Zurück zum Zitat Grote VA, Kaaks R, Nieters A, Tjonneland A, Halkjaer J, Overvad K, Skjelbo Nielsen MR, Boutron-Ruault MC, Clavel-Chapelon F, Racine A, Teucher B, Becker S, Pischon T, Boeing H, Trichopoulou A, Cassapa C, Stratigakou V, Palli D, Krogh V, Tumino R, Vineis P, Panico S, Rodriguez L, Duell EJ, Sanchez MJ, Dorronsoro M, Navarro C, Gurrea AB, Siersema PD, Peeters PH, Ye W, Sund M, Lindkvist B, Johansen D, Khaw KT, Wareham N, Allen NE, Travis RC, Fedirko V, Jenab M, Michaud DS, Chuang SC, Romaguera D, Bueno-de-Mesquita HB, Rohrmann S (2012) Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 106(11):1866–1874. doi:10.1038/bjc.2012.172 PubMedCentralPubMedCrossRef Grote VA, Kaaks R, Nieters A, Tjonneland A, Halkjaer J, Overvad K, Skjelbo Nielsen MR, Boutron-Ruault MC, Clavel-Chapelon F, Racine A, Teucher B, Becker S, Pischon T, Boeing H, Trichopoulou A, Cassapa C, Stratigakou V, Palli D, Krogh V, Tumino R, Vineis P, Panico S, Rodriguez L, Duell EJ, Sanchez MJ, Dorronsoro M, Navarro C, Gurrea AB, Siersema PD, Peeters PH, Ye W, Sund M, Lindkvist B, Johansen D, Khaw KT, Wareham N, Allen NE, Travis RC, Fedirko V, Jenab M, Michaud DS, Chuang SC, Romaguera D, Bueno-de-Mesquita HB, Rohrmann S (2012) Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 106(11):1866–1874. doi:10.​1038/​bjc.​2012.​172 PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397PubMedCrossRef Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397PubMedCrossRef
5.
Zurück zum Zitat Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstrom G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jorgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. The New England journal of medicine 367(14):1310–1320. doi:10.1056/NEJMoa1107477 PubMedCrossRef Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstrom G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jorgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. The New England journal of medicine 367(14):1310–1320. doi:10.​1056/​NEJMoa1107477 PubMedCrossRef
6.
Zurück zum Zitat Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3):327–334PubMedCrossRef Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3):327–334PubMedCrossRef
7.
Zurück zum Zitat Al-Delaimy WK, Jansen EH, Peeters PH, van der Laan JD, van Noord PA, Boshuizen HC, van der Schouw YT, Jenab M, Ferrari P, Bueno-de-Mesquita HB (2006) Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers 11:370–382PubMedCrossRef Al-Delaimy WK, Jansen EH, Peeters PH, van der Laan JD, van Noord PA, Boshuizen HC, van der Schouw YT, Jenab M, Ferrari P, Bueno-de-Mesquita HB (2006) Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers 11:370–382PubMedCrossRef
8.
Zurück zum Zitat Block G, Dietrich M, Norkus E, Jensen C, Benowitz NL, Morrow JD, Hudes M, Packer L (2006) Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology 17:404–412PubMedCrossRef Block G, Dietrich M, Norkus E, Jensen C, Benowitz NL, Morrow JD, Hudes M, Packer L (2006) Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology 17:404–412PubMedCrossRef
9.
Zurück zum Zitat Cava F, Gonzalez C, Pascual MJ, Navajo JA, Gonzalez-Buitrago JM (2000) Biological variation of interleukin 6 (IL-6) and soluble interleukin 2 receptor (sIL2R) in serum of healthy individuals. Cytokine 12(9):1423–1425. doi:10.1006/cyto.2000.0714 PubMedCrossRef Cava F, Gonzalez C, Pascual MJ, Navajo JA, Gonzalez-Buitrago JM (2000) Biological variation of interleukin 6 (IL-6) and soluble interleukin 2 receptor (sIL2R) in serum of healthy individuals. Cytokine 12(9):1423–1425. doi:10.​1006/​cyto.​2000.​0714 PubMedCrossRef
10.
12.
Zurück zum Zitat Epstein MM, Breen EC, Magpantay L, Detels R, Lepone L, Penugonda S, Bream JH, Jacobson LP, Martinez-Maza O, Birmann BM (2013) Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. Cancer Epidemiol Biomarkers Prev 22(11):2009–2015. doi:10.1158/1055-9965.EPI-13-0379 PubMedCrossRef Epstein MM, Breen EC, Magpantay L, Detels R, Lepone L, Penugonda S, Bream JH, Jacobson LP, Martinez-Maza O, Birmann BM (2013) Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. Cancer Epidemiol Biomarkers Prev 22(11):2009–2015. doi:10.​1158/​1055-9965.​EPI-13-0379 PubMedCrossRef
13.
Zurück zum Zitat Gonzalez C, Cava F, Ayllon A, Guevara P, Navajo JA, Gonzalez-Buitrago JM (2001) Biological variation of interleukin-1beta, interleukin-8 and tumor necrosis factor-alpha in serum of healthy individuals. Clinical Chem Lab Med 39(9):836–841. doi:10.1515/CCLM.2001.139 CrossRef Gonzalez C, Cava F, Ayllon A, Guevara P, Navajo JA, Gonzalez-Buitrago JM (2001) Biological variation of interleukin-1beta, interleukin-8 and tumor necrosis factor-alpha in serum of healthy individuals. Clinical Chem Lab Med 39(9):836–841. doi:10.​1515/​CCLM.​2001.​139 CrossRef
14.
Zurück zum Zitat Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, Shore RE, Marrangoni A, Toniolo P, Lokshin AE, Arslan AA (2009) Reproducibility of serum cytokines and growth factors. Cytokine 45:44–49PubMedCentralPubMedCrossRef Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, Shore RE, Marrangoni A, Toniolo P, Lokshin AE, Arslan AA (2009) Reproducibility of serum cytokines and growth factors. Cytokine 45:44–49PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Ho GY, Xue XN, Burk RD, Kaplan RC, Cornell E, Cushman M (2005) Variability of serum levels of tumor necrosis factor-alpha, interleukin 6, and soluble interleukin 6 receptor over 2 years in young women. Cytokine 30:1–6PubMedCrossRef Ho GY, Xue XN, Burk RD, Kaplan RC, Cornell E, Cushman M (2005) Variability of serum levels of tumor necrosis factor-alpha, interleukin 6, and soluble interleukin 6 receptor over 2 years in young women. Cytokine 30:1–6PubMedCrossRef
17.
Zurück zum Zitat Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y, Kario K (2000) Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993–1998. Jpn Circ J 64(4):303–308PubMedCrossRef Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y, Kario K (2000) Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993–1998. Jpn Circ J 64(4):303–308PubMedCrossRef
18.
Zurück zum Zitat Lee SA, Kallianpur A, Xiang YB, Wen W, Cai Q, Liu D, Fazio S, Linton MF, Zheng W, Shu XO (2007) Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev 16:2464–2470PubMedCrossRef Lee SA, Kallianpur A, Xiang YB, Wen W, Cai Q, Liu D, Fazio S, Linton MF, Zheng W, Shu XO (2007) Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev 16:2464–2470PubMedCrossRef
19.
Zurück zum Zitat Nasermoaddeli A, Sekine M, Kagamimori S (2006) Intra-individual variability of high-sensitivity C-reactive protein: age-related variations over time in Japanese subjects. Circ J 70:559–563PubMedCrossRef Nasermoaddeli A, Sekine M, Kagamimori S (2006) Intra-individual variability of high-sensitivity C-reactive protein: age-related variations over time in Japanese subjects. Circ J 70:559–563PubMedCrossRef
21.
Zurück zum Zitat Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47:444–450PubMed Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47:444–450PubMed
22.
Zurück zum Zitat Rao KM, Pieper CS, Currie MS, Cohen HJ (1994) Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. Am J Clin Pathol 102:802–805PubMed Rao KM, Pieper CS, Currie MS, Cohen HJ (1994) Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. Am J Clin Pathol 102:802–805PubMed
24.
Zurück zum Zitat Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ (2002) Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 11(8):745–752PubMed Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ (2002) Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 11(8):745–752PubMed
27.
Zurück zum Zitat Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428PubMedCrossRef Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428PubMedCrossRef
28.
Zurück zum Zitat Rosner B (2000) Fundamentals of biostatistics, vol 5th. Vol book, whole. Duxbury, Pacific Grove Rosner B (2000) Fundamentals of biostatistics, vol 5th. Vol book, whole. Duxbury, Pacific Grove
29.
Zurück zum Zitat Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR (1992) Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods 153(1–2):115–124PubMedCrossRef Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR (1992) Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods 153(1–2):115–124PubMedCrossRef
30.
Zurück zum Zitat Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-Reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMedCrossRef Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-Reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMedCrossRef
31.
Zurück zum Zitat White E (2011) Measurement error in biomarkers: sources, assessment, and impact on studies. IARC Sci Publ 163:143–161PubMed White E (2011) Measurement error in biomarkers: sources, assessment, and impact on studies. IARC Sci Publ 163:143–161PubMed
32.
Zurück zum Zitat White E, Armstrong BK, Saracci R (2008) Principles of exposure measurement in epidemiology, 2nd edn, vol book, whole. Oxford University Press, USA White E, Armstrong BK, Saracci R (2008) Principles of exposure measurement in epidemiology, 2nd edn, vol book, whole. Oxford University Press, USA
33.
Zurück zum Zitat de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V (2009) Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 10:52PubMedCentralPubMedCrossRef de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V (2009) Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 10:52PubMedCentralPubMedCrossRef
34.
35.
Zurück zum Zitat House RV (2001) Cytokine measurement techniques for assessing hypersensitivity. Toxicology 158(1–2):51–58PubMedCrossRef House RV (2001) Cytokine measurement techniques for assessing hypersensitivity. Toxicology 158(1–2):51–58PubMedCrossRef
Metadaten
Titel
Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage
verfasst von
Sheetal Hardikar
Xiaoling Song
Mario Kratz
Garnet L. Anderson
Patricia L. Blount
Brian J. Reid
Thomas L. Vaughan
Emily White
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 8/2014
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0396-0

Weitere Artikel der Ausgabe 8/2014

Cancer Causes & Control 8/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.